Mirtazapina Almus (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Almus, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral dosage form for oral use. It treats major depressive disorder in adult patients and helps improve mood, sleep and appetite.

GNH USA supplies Mirtazapina Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapina Almus is a NaSSA antidepressant indicated for conditions within the depressive disorder spectrum. - Major depressive disorder: reduces depressive symptoms and improves overall functioning in adults. - Depressive episodes with insomnia: alleviates low mood while promoting sleep continuity. - Depression with anxiety features: helps manage both mood and anxiety components in affected patients.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Seizures - Cardiovascular abnormalities such as QT prolongation

Before initiating therapy, clinicians should consider several safety aspects. - Hepatic function: assess liver enzymes and adjust use if severe impairment is present. - Weight monitoring: track body weight regularly due to the risk of weight gain. - Suicidal ideation: monitor patients for emergent suicidal thoughts, particularly during the first weeks. - Elderly patients: use caution because sedation may increase fall risk. - Discontinuation: avoid abrupt cessation; taper under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., tramadol, linezolid): may precipitate serotonin syndrome. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Strong CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may increase mirtazapine plasma levels. - CYP inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Antihistamines: can enhance sedation.